Month: November 2023

AIBILI is proud to perform a study on the effectiveness of educational materials available for Vabysmo®, Eylea® and Lucentis®.

The MARVEL Study, supported by INFARMED, I.P., is conducted by the Coimbra Regional Pharmacovigilance Unit of AIBILI and aims to evaluate the effectiveness of educational materials for healthcare professionals and the target general population, as additional measures of risk minimization for the drugs Vabysmo® (faricimab), Eylea® (aflibercept) and Lucentis® (ranibizumab).

More information: https://www.infarmed.pt/web/infarmed/infarmed/-/journal_content/56/15786/9521902

Presentations:

• Abnormal retinal fluid in eyes with diabetic center-involved macular edema

Prof. José Cunha-Vaz

 

• A Conversion Model for OCTA Vessel Density Metrics in Diabetic Eyes: Angiovue vs Cirrus Angioplex

Doutora Ana Rita Santos

 

• Statins and genetics in the risk of progression of age-related macular degeneration – The Coimbra Eye Study

Dra. Patrícia Barreto

 

• Combination of Ultra-widefield Colour Fundus Photography and Optical Coherence Tomography Angiography identify different subtypes of non-proliferative diabetic retinopathy

Dra. Ana Almeida

 

Posters:

• CLARUS (or Wide-Field Fundus Imaging) Improves ETDRS Grading with Classic 7-fields Fundus Photographs

Dra. Marta Lopes

 

Audio narrated free paper:

• Statin intake time and risk for progression of age-related macular degeneration – a comparison of two Cox regression models applied to the Coimbra Eye Study

Doutora Rita Coimbra

AIBILI will be presenting at EVOLVE – Digital Transformation Summit 2023 the EVICR.net Eye Platform. This summit will be organised by APDC on October 11, 2023, in Lisbon, Portugal. The EVICR.net Eye Platform is a long-term initiative to collect longitudinal anonymised clinical data and eye images from the network’s centers across Europe. The data platform will be available for analysis by all EVICR.net partners to develop a better understanding of the progression of eye diseases and new ways to improve patient care and prevent vision loss.
Boehringer Ingelheim is funding the EVICR.net Eye Platform and a pilot study that is collecting and will analyze data in patients with intermediate AMD or early atrophic AMD.
Learn more at: https://www.evicr.net/eyeplatform/

AIBILI was present at this ERA4Health workshop – Analysis of bottlenecks and challenges in designing and conducting investigator-initiated multinational clinical studies – through Dr. Cecília Martinho and Dr. Joana Tavares, which took place in Paris, France, on 15-16/09/2023. Challenges in designing and conducting investigator-initiated multinational clinical studies were discussed.